AgingResearch.NewsJoin free

2026 dyslipidemia guideline

2026 dyslipidemia guideline has been studied in 1 paper since 2026: 1 observational study in people; 1 in the past year. The newest story, Nov 9, 2026: “Updated guidelines favor cholesterol drugs for more US adults”.

Exposure

1 paper studies it1 findingUpdated

1 new paper in 30 daysSee all 1 papers on 2026 dyslipidemia guideline

At a glance

The findings reach people, from one lab or study. 1 lab in 1 country.

“Overall, the 2026 framework newly identified 15.9 million (14.1-17.7) additional adults for treatment consideration”
Population-Level Redistribution of Lipid-Lowering Therapy Recommendations Under Updated Dyslipidemia GuidelinesAHA Scientific Sessions 2026 abstract2026doi:10.1161/circ.154.suppl_1.9877
Humans: a single group. Cells, worms or flies and mice: nothing yet.

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

  • 1 lab in 1 country
  • Humans1

What did studies of 2026 dyslipidemia guideline find?

1

Studies of 2026 dyslipidemia guideline measured one outcome, Adults identified for lipid-lowering therapy consideration.

Adults identified for lipid-lowering therapy consideration

upin humans1

1 study

  1. 2026 dyslipidemia guideline is linked with higher adults identified for lipid-lowering therapy consideration in humans (Untreated U.S. adults; 2026 versus 2018 guideline framework) (15.9 million (14.1-17.7) additional adults).

    “Overall, the 2026 framework newly identified 15.9 million (14.1-17.7) additional adults for treatment consideration”

    HumansUntreated U.S. adults; 2026 versus 2018 guideline frameworkn = 6,118

    Updated guidelines favor cholesterol drugs for more US adults

    AHA Scientific Sessions 2026 abstract

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 11 paper in 12 months
AHA Scientific Sessions 2026 Abstract

Updated guidelines favor cholesterol drugs for more US adults

The 2026 framework identified 15.9 million more untreated US adults for consideration of cholesterol-lowering medication than the 2018 framework.The 2026 framework identified 15.9 million more untreated US adults for consideration of cholesterol-lowering medication than the 2018 framework.

Cross-sectional · 6,118 peopleIndustry & policy
Paper

Related